The active phosphorylated form of FTY720/fingolimod, a prodrug treating multiple sclerosis, could reduce FASN expression by histone acetylation alteration, inhibit ceramide production and hepatic steatosis in diet-induced NAFLD mice [78]. Here, FASN is linked to fatty liver disease.